Grail multicancer detection test wins FDA advisers’ backing
Published . Updated .
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
Directly affected
- GRAL Grail
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
Source: BioPharma Dive
Acadia Healthcare (ACHC) since this story, compared with the market
Since the first closing price after “Grail multicancer detection test wins FDA advisers’ backing,” Acadia Healthcare (ACHC) is +7.44%. The S&P 500 fund (SPY) is -0.62% over the same days, a +8.05% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 24 Sep 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Where this story sits: Taiwan Strait
Taiwan Strait has 48 linked stories in the last 7 days and 48 in the last 30 on the page that also carries “Grail multicancer detection test wins FDA advisers’ backing.” The recent pace is rising.
Who gains and who pays if Taiwan Strait stays in the story
Companies tied to this story
- ACHC Acadia Healthcare
For “Grail multicancer detection test wins FDA advisers’ backing,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Grail multicancer detection test wins FDA advisers’ backing.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Grail multicancer detection test wins FDA advisers’ backing,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Grail multicancer detection test wins FDA advisers’ backing,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- CRDF Cardiff Oncology
Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Grail multicancer detection test wins FDA advisers’ backing.” Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Grail multicancer detection test wins FDA advisers’ backing,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Grail multicancer detection test wins FDA advisers’ backing” reaches Acadia Healthcare (ACHC)
On 24 Sep 2026, “Grail multicancer detection test wins FDA advisers’ backing” is the story that connects Acadia Healthcare (ACHC) to Taiwan Strait.
For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
How strong the case is around Acadia Healthcare (ACHC)
46 out of 100
“Grail multicancer detection test wins FDA advisers’ backing” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.